Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Lampalizumab
Подписчиков: 0, рейтинг: 0
Monoclonal antibody | |
---|---|
Type | Fab fragment |
Source | Humanized (from mouse) |
Target | CFD |
Clinical data | |
Routes of administration |
Intravitreal |
ATC code |
|
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C2068H3214N546O676S13 |
Molar mass | 46958.39 g·mol−1 |
Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.
One of the two Phase 3 clinical trials (Spectri) was interrupted on September 8, 2017 due to failure to meet primary end point. The second Phase 3 clinical trial (Chroma) also failed to meet its primary end point.
These two failures have called into question whether complement inhibition is a sound strategy for geographic atrophy.